477 related articles for article (PubMed ID: 20116611)
61. Pharmacokinetics and inhibitory quotient of atazanavir/ritonavir versus lopinavir/ritonavir in HIV-infected, treatment-naive patients who participated in the CASTLE Study.
Zhu L; Liao S; Child M; Zhang J; Persson A; Sevinsky H; Eley T; Xu X; Krystal M; Farajallah A; McGrath D; Molina JM; Bertz R
J Antimicrob Chemother; 2012 Feb; 67(2):465-8. PubMed ID: 22121190
[TBL] [Abstract][Full Text] [Related]
62. Virological efficacy and safety of antiretroviral therapy-switch to atazanavir-based regimen: a review of the literature.
Stephan C
Expert Opin Pharmacother; 2012 Nov; 13(16):2355-67. PubMed ID: 23050508
[TBL] [Abstract][Full Text] [Related]
63. High incidence of renal stones among HIV-infected patients on ritonavir-boosted atazanavir than in those receiving other protease inhibitor-containing antiretroviral therapy.
Hamada Y; Nishijima T; Watanabe K; Komatsu H; Tsukada K; Teruya K; Gatanaga H; Kikuchi Y; Oka S
Clin Infect Dis; 2012 Nov; 55(9):1262-9. PubMed ID: 22820542
[TBL] [Abstract][Full Text] [Related]
64. Cost effectiveness of lopinavir/ritonavir compared with atazanavir in antiretroviral-naive patients: modelling the combined effects of HIV and heart disease.
Simpson KN; Luo MP; Chumney EC; King MS; Brun S
Clin Drug Investig; 2007; 27(1):67-74. PubMed ID: 17177581
[TBL] [Abstract][Full Text] [Related]
65. Protease inhibitors as preferred initial regimen for antiretroviral-naive HIV patients.
Tejerina F; Bernaldo de Quirós JC
AIDS Rev; 2011; 13(4):227-33. PubMed ID: 21975358
[TBL] [Abstract][Full Text] [Related]
66. Chronic interstitial nephritis in an HIV type-1-infected patient receiving ritonavir-boosted atazanavir.
Viglietti D; Verine J; De Castro N; Scemla A; Daudon M; Glotz D; Pillebout E
Antivir Ther; 2011; 16(1):119-21. PubMed ID: 21311116
[TBL] [Abstract][Full Text] [Related]
67. A randomized comparative 96-week trial of boosted atazanavir versus continued boosted protease inhibitor in HIV-1 patients with abdominal adiposity.
Moyle GJ; Andrade-Villanueva J; Girard PM; Antinori A; Salvato P; Bogner JR; Hay P; Santos J; Astier L; Pans M; Balogh A; Biguenet S;
Antivir Ther; 2012; 17(4):689-700. PubMed ID: 22388634
[TBL] [Abstract][Full Text] [Related]
68. Atazanavir: in pediatric patients with HIV-1 infection.
Deeks ED
Paediatr Drugs; 2012 Apr; 14(2):131-41. PubMed ID: 22292486
[TBL] [Abstract][Full Text] [Related]
69. [Safety of atazanavir in patients with HIV and hepatitis B and/or C virus coinfection].
Rivero A; Camacho A; Pérez-Camacho I; Torre-Cisneros J
Enferm Infecc Microbiol Clin; 2008 Dec; 26 Suppl 17():45-8. PubMed ID: 20116617
[TBL] [Abstract][Full Text] [Related]
70. Cost-effectiveness of atazanavir/ritonavir compared with lopinavir/ritonavir in treatment-naïve human immunodeficiency virus-1 patients in Sweden.
Thuresson PO; Heeg B; Lescrauwaet B; Sennfält K; Alaeus A; Neubauer A
Scand J Infect Dis; 2011 Apr; 43(4):304-12. PubMed ID: 21231811
[TBL] [Abstract][Full Text] [Related]
71. Effects of ritonavir-boosted darunavir vs. ritonavir-boosted atazanavir on lipid and glucose parameters in HIV-negative, healthy volunteers.
Tomaka F; Lefebvre E; Sekar V; Van Baelen B; Vangeneugden T; Vandevoorde A; Diego Miralles G
HIV Med; 2009 May; 10(5):318-27. PubMed ID: 19210693
[TBL] [Abstract][Full Text] [Related]
72. The relation between treatment outcome and efavirenz, atazanavir or lopinavir exposure in the NORTHIV trial of treatment-naïve HIV-1 infected patients.
Josephson F; Andersson MC; Flamholc L; Gisslén M; Hagberg L; Ormaasen V; Sönnerborg A; Vesterbacka J; Böttiger Y
Eur J Clin Pharmacol; 2010 Apr; 66(4):349-57. PubMed ID: 19967342
[TBL] [Abstract][Full Text] [Related]
73. [Utility of atazanavir in special populations].
Antela López A
Enferm Infecc Microbiol Clin; 2008 Dec; 26 Suppl 17():49-54. PubMed ID: 20116618
[TBL] [Abstract][Full Text] [Related]
74. Impact of lopinavir/ritonavir use on antiretroviral resistance in recent clinical practice.
Lambert-Niclot S; Masquelier B; Cohen Codar I; Soulie C; Delaugerre C; Morand-Joubert L; Charpentier C; Ferre V; Plantier JC; Montes B; Carret S; Perrot V; Peytavin G; Costagliola D; Calvez V; Marcelin AG;
J Antimicrob Chemother; 2012 Oct; 67(10):2487-93. PubMed ID: 22733652
[TBL] [Abstract][Full Text] [Related]
75. Atazanavir: its role in HIV treatment.
Wood R
Expert Rev Anti Infect Ther; 2008 Dec; 6(6):785-96. PubMed ID: 19053892
[TBL] [Abstract][Full Text] [Related]
76. Comparative gender analysis of the efficacy and safety of atazanavir/ritonavir and lopinavir/ritonavir at 96 weeks in the CASTLE study.
Squires KE; Johnson M; Yang R; Uy J; Sheppard L; Absalon J; McGrath D
J Antimicrob Chemother; 2011 Feb; 66(2):363-70. PubMed ID: 21148235
[TBL] [Abstract][Full Text] [Related]
77. Broadening the perspective when assessing evidence on boosted protease inhibitor-based regimens for initial antiretroviral therapy.
Hornberger J; Simpson K; Shewade A; Dietz B; Baran R; Podsadecki T
Adv Ther; 2010 Nov; 27(11):763-73. PubMed ID: 20931365
[TBL] [Abstract][Full Text] [Related]
78. Treatment durability, effectiveness, and safety with atazanavir/ritonavir-based HAART regimen in treatment-naïve HIV-infected patients.
Tremblay C; Trottier B; Rachlis A; Baril JG; Loutfy M; Lalonde R; Sampalis JS; Boulerice F
HIV Clin Trials; 2011; 12(3):151-60. PubMed ID: 21684855
[TBL] [Abstract][Full Text] [Related]
79. Efficacy and safety of atazanavir, with or without ritonavir, as part of once-daily highly active antiretroviral therapy regimens in antiretroviral-naive patients.
Malan DR; Krantz E; David N; Wirtz V; Hammond J; McGrath D;
J Acquir Immune Defic Syndr; 2008 Feb; 47(2):161-7. PubMed ID: 17971713
[TBL] [Abstract][Full Text] [Related]
80. Unboosted atazanavir for treatment of HIV infection: rationale and recommendations for use.
Focà E; Ripamonti D; Motta D; Torti C
Drugs; 2012 Jun; 72(9):1161-73. PubMed ID: 22646049
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
